Logo

AGIO

Agios Pharmaceuticals, Inc.

AGIO

Agios Pharmaceuticals, Inc. • NASDAQ
$29.20 ▲ 0.55% (+0.16)
Market Cap $1.70 B
52w High $62.45
52w Low $22.24
Dividend Yield 0%
P/E -4.17
Volume 500.59K
Outstanding Shares 58.31M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $12.88M ▲ $128.07M ▼ $-103.433M ▲ -803.051% ▲ $-1.78 ▲ $-102.059M ▲
Q2-2025 $12.455M ▲ $136.55M ▲ $-112.02M ▼ -899.398% ▲ $-1.93 ▼ $-110.761M ▼
Q1-2025 $8.726M ▼ $114.27M ▼ $-89.289M ▲ -1.023K% ▼ $-1.55 ▲ $-105.351M ▲
Q4-2024 $10.73M ▲ $134.507M ▲ $-96.523M ▼ -899.562% ▼ $-1.69 ▼ $-123.67M ▼
Q3-2024 $8.964M $110.992M $947.915M 10.575K% $16.65 $-101.466M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $952.86M ▲ $1.386B ▼ $101.375M ▼ $1.284B ▼
Q2-2025 $938.937M ▲ $1.471B ▼ $101.682M ▲ $1.37B ▼
Q1-2025 $893.375M ▼ $1.556B ▼ $88.99M ▼ $1.467B ▼
Q4-2024 $893.71M ▼ $1.663B ▼ $122.243M ▼ $1.541B ▼
Q3-2024 $1.005B $1.792B $165.122M $1.627B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-103.433M ▲ $-88.151M ▼ $95.555M ▲ $4.435M ▲ $11.839M ▲ $-89.706M ▼
Q2-2025 $-112.02M ▼ $-77.124M ▲ $78.966M ▼ $65K ▼ $1.907M ▼ $-77.999M ▲
Q1-2025 $-89.289M ▲ $-111.489M ▲ $112.587M ▲ $1.619M ▼ $2.717M ▲ $-112.255M ▲
Q4-2024 $-96.523M ▼ $-133.167M ▼ $-49.158M ▼ $4.842M ▲ $-177.483M ▼ $-134.134M ▼
Q3-2024 $947.915M $-84.218M $250.793M $2.637M $169.212M $-84.637M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Product
Product
 $10.00M ▲$10.00M ▲$10.00M ▲$10.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Agios looks like a classic R&D‑heavy biotech: very little product revenue today, but sizable ongoing operating losses. The company has been spending steadily on research, development, and commercialization, and that has kept operating results in the red for several years. The swings in reported profit and earnings per share mainly reflect one‑time items and past asset sales or deals, not a stable, profitable business from drug sales. In other words, underlying operations are still loss‑making, and the recent headline profit is unlikely to represent a new, steady earnings baseline.

Balance Sheet

Balance Sheet The balance sheet shows a company that is well‑capitalized but still dependent on external funding and partnerships over time. Total assets and shareholder equity increased meaningfully in the most recent year, likely helped by transactions or financings, which strengthens the financial cushion. Cash on hand is modest relative to ongoing losses, and debt is small but present, so leverage is not a major concern right now. The main question is not solvency today, but how long the current capital base can support R&D and commercialization before additional funding may be needed.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, reflecting the cost of running trials, doing research, and building the commercial effort, while product revenue is still very limited. Free cash flow is also negative but fairly stable over time, which suggests disciplined but ongoing cash burn. Capital spending needs are low, so most cash outflow is tied directly to people, trials, and development programs. The overall picture is a company that must keep drawing down its cash reserves or raise new capital while it works to expand PYRUKYND® and advance its pipeline.

Competitive Edge

Competitive Edge Agios has carved out a focused niche in rare blood and metabolic diseases, built on deep expertise in cellular metabolism. Its main advantage today is being first with a disease‑modifying oral therapy for pyruvate kinase deficiency, which gives it a lead in this very specialized market and creates meaningful barriers for new entrants. A concentrated rare‑disease strategy, combined with a specialized scientific platform, supports a defensible position. On the other hand, the company is still small, with one primary commercial product and heavy reliance on future label expansions and pipeline success, so it remains vulnerable to setbacks, pricing pressure, and competition from larger pharma or new technologies.

Innovation and R&D

Innovation and R&D Innovation is the core of Agios’s story. The company has built a strong scientific platform around manipulating cellular metabolism, especially activating pyruvate kinase, and is using it to pursue multiple rare blood disorders. PYRUKYND® is a clear proof‑of‑concept for this approach, and the pipeline aims to extend the same biology into conditions like thalassemia, sickle cell disease, and myelodysplastic syndromes. However, recent mixed data in sickle cell disease highlight the inherent risk: even promising science can produce uneven clinical outcomes and regulatory uncertainty. Agios is also working on earlier‑stage programs in other rare diseases and aims to keep a steady flow of new candidates, which, if successful, could diversify its portfolio but will also require sustained spending and careful trial design.

Summary

Agios is a high‑risk, high‑uncertainty biotech that has transformed itself from an oncology player into a focused rare‑disease company built around cellular metabolism. Financially, it remains loss‑making with predictable cash burn and limited product revenue, supported by a strengthened equity base and a modest amount of debt. Its main asset is a first‑in‑class therapy in a niche indication and a pipeline that tries to leverage the same metabolic know‑how across several rare blood disorders. The upside case depends heavily on expanding PYRUKYND® into larger patient groups and successfully advancing other candidates, while the downside centers on clinical or regulatory setbacks, slower‑than‑expected uptake, and the ongoing need for capital. Investors typically view companies like Agios through a long‑term, event‑driven lens, given the binary nature of trial outcomes and approvals.

NEWS

November 19, 2025 · 7:00 AM UTC

Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease

Read more

November 3, 2025 · 9:01 AM UTC

Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition

Read more

October 30, 2025 · 6:30 AM UTC

Agios Reports Third Quarter 2025 Financial Results and Provides Business Update

Read more

October 18, 2025 · 10:00 AM UTC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO

Read more

October 17, 2025 · 8:15 AM UTC

Avanzanite Bioscience's Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia

Read more